Company Information

Location

Cambridge, MA

CEO

Rahul Ballal

Website

imaratx.com

Social

LinkedIn

Arix Representative

Imara is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease (SCD) is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease.

Early clinical data in SCD patients support the potential for IMR-687 to improve health outcomes and possibly ameliorate disease pathology. The mechanism of IMR-687 is differentiated from other therapies in development by its dual action on both red and white blood cells. Imara has received Orphan Drug Designation from the US FDA for IMR-687 for SCD and has initiated a phase 2a clinical trial in adult patients with SCD.